Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Ian Mortimer and CFO Sherry Aulin will speak at three upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Ian Mortimer and CFO Sherry Aulin will speak at three upcoming virtual investor conferences. The Guggenheim 3rd Annual Neuro/Immunology Conference will take place on November 15, 2021, featuring one-on-one meetings. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, including a fireside chat at 1:20 pm ET. Lastly, the Jefferies London Healthcare Conference is set for November 18, 2021, with an on-demand fireside chat starting at 8:00 am GMT. For updates, visit investor.xenon-pharma.com.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was -0.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will participate virtually in the following investor conferences:
- Guggenheim 3rd Annual Neuro/Immunology Conference on Monday, November 15, 2021 (one-on-one meetings only)
- Stifel 2021 Virtual Healthcare Conference on Wednesday, November 17, 2021, with fireside chat presentation at 1:20 pm ET
- Jefferies London Healthcare Conference on Thursday, November 18, 2021, with on-demand streaming of fireside chat presentation beginning at 8:00 am GMT / 3:00 am ET
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.